Quick Answer
Atara Biotherapeutics, Inc. reported Operating Income of $35.86 million for fiscal year 2025.
Atara Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $35.86M | +143.0% |
| 2024 | -$83.44M | +69.8% |
| 2023 | -$276.01M | +1.6% |
| 2022 | -$280.51M | +17.6% |
| 2021 | -$340.46M | -10.2% |
| 2020 | -$309.05M | -4.5% |
| 2019 | -$295.68M | -24.7% |
| 2018 | -$237.11M | -95.1% |
| 2017 | -$121.53M | -49.6% |
| 2016 | -$81.24M | -39.0% |
| 2015 | -$58.45M | -107.6% |
| 2014 | -$28.16M | -226.8% |
| 2013 | -$8.62M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.57M | +83.6% | -211.8% |
| June 30, 2025 | $3.20M | +117.5% | -91.8% |
| March 31, 2025 | $38.80M | +224.2% | +278.3% |
| September 30, 2024 | -$21.76M | +68.7% | -19.3% |
| June 30, 2024 | -$18.23M | +74.5% | +41.7% |
| March 31, 2024 | -$31.25M | +58.3% | +55.1% |
| September 30, 2023 | -$69.61M | +17.7% | +2.5% |
| June 30, 2023 | -$71.41M | -122.3% | +4.8% |
- Atara Biotherapeutics, Inc. showed an increase of +143.0% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Atara Biotherapeutics, Inc.’s operating income has grown by 516.3% (from -$8.62 million to $35.86 million).
- The most recent figure is from Atara Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: